Healthcare Professionals
Please log in for special information and services

Facts & Figures  

AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.

Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the German health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

Germany occupies a particular position among many countries where AOP Orphan is represented since it was one of the first expansion territory. The company began its development in Germany in 2011 and was transformed into a legal entity in 2018. 

AOP Orphan Germany is a team of around eight employees in the Marketing & Sales, Medical Affairs and Market Access in HematoOncology division. 

 

4mio
people
4 mio affected people
In Europe those diseases that occur in less than 5 per 10,000 residents are defined as rare diseases. More than 4 mio people have been affected with rare diseases in Germany.
HematoOncology 
As a specialist for rare diseases AOP Orphan provides innovative solutions in Germany in the therapeutic area of HematoOncology.
HON
therapeutic area
9
PRODUCTS
3 Innovative Products
AOP Orphan Germany provides nine innovative treatments of rare diseases and symptoms.

Vision & Mission

Milestones

History of more than 20 years means many significant milestones — in research,  social, business spheres and regulatory affairs — that were and are important for AOP Orphan.

2020

AOP Orphan Group

2019

BESREMi® Approval

2018

Treprostinil and PAH

2017

Landiolol approval

2016

Pitolisant approval

2015

Beta-blocker for severe sepsis

2013

Start of the PROUD PV Study

2012

Nabilone Approval in Austria

2010

Tetrabenazine Approval in Central Europe

2010

UDCA Designation

2008

Renaissance of Interferon (IFNα)

2005

JAK2 Discovery

2005

Prostacyclin Analogues Approval

2004

European Union Expansion

2001

1st Approval of Anagrelide in Europe

1999

The Orphan Regulation EC no 141/2000

1996

Foundation of AOP Orphan in Vienna

Corporate culture

Thanks to many years of experience in the provision of complex and individualized treatments, AOP Orphan gained special expertise and market presence in the field of rare diseases.

Since its very start AOP Orphan has borne the corporate responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases.  We at AOP Orphan conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Orphan corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researchers, physicians, therapists, caregivers and, patient organizations.

AOP Orphan is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.

Mag. Andreas Steiner Group CEO AOP Orphan International AG

From its inception AOP Orphan's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Orphan’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.